Selumetinib Cracks Door to Targeted Therapy for KRAS-Mutant NSCLC
June 18, 2012|Oncology Practice
Author and Disclosure Information
AT THE ANNUAL MEETING OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY
The safety analysis was based on 44 selumetinib and 43 controls, and the efficacy analysis on 43 and 40 patients, respectively.
The majority of patients, or 88%, were current or former smokers, roughly half had a WHO performance status 0, and 82% had adenocarcinoma histology. Their median age was 59 years.
The study was sponsored by AstraZeneca. Dr. Jänne reported a consultant/advisory role with AstraZeneca; several of his coauthors reported financial relationships with firms including employment or stock ownership with AstraZeneca. Dr. Neal reported research funding from Genentech.
